Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
585 studies found for:    G250
Show Display Options
Rank Status Study
1 Terminated Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: G250 peptide;   Drug: IL-2
2 Unknown  Treatment of Patients With Advanced Renal Cancer With a Radio-labeled Antibody, Yttrium-90 Conjugated Chimeric G250
Conditions: Renal Cell Carcinoma;   Kidney Neoplasm;   Renal Cancer;   Kidney Cancer
Intervention: Drug: Yttrium-90 conjugated chimeric G250 (90Y-cG250)
3 Completed
Has Results
Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
Conditions: Renal Cell Carcinoma;   Kidney Cancer
Interventions: Drug: 124-Iodine-cG250 (124I-cG250);   Procedure: CT
4 Completed Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
Condition: Kidney Cancer
Intervention: Radiation: iodine I 131 chimeric monoclonal antibody G-250
5 Completed Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
Condition: Kidney Cancer
Interventions: Biological: girentuximab;   Other: placebo
6 Completed Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
Conditions: Cancer of Kidney;   Kidney Cancer;   Renal Cancer;   Neoplasms, Kidney;   Renal Neoplasms
Intervention: Drug: 124-Iodine-cG250 (124I-cG250)
7 Completed Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250
Condition: Clear Cell Renal Cell Carcinoma
Interventions: Drug: Sorafenib;   Drug: 111Indium-bevacizumab;   Drug: 111Indium-cG250
8 Completed Brivanib Metastatic Renal Cell Carcinoma
Condition: Male and Female Subjects 18 Years of Age and Older With Metastatic Renal Cell Carcinoma. Eligible Patients Must Have Undergone and Failed Prior Treatment.
Interventions: Drug: Brivanib alaninate;   Genetic: Polymerase chain reaction;   Other: Iodine I 124 chimeric monoclonal antibody G250;   Procedure: Positron emission tomography/computed tomography;   Genetic: Protein expression analysis;   Other: Immunohistochemistry
9 Terminated Study of Safety and Effects of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Biological: Chimeric monoclonal antibody cG250;   Drug: Sunitinib malate
10 Recruiting Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
Condition: Renal Cancer
Intervention: Drug: 124IcG250
11 Terminated Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer
Conditions: Metastatic Kidney Cancer;   Metastatic Renal Cell Carcinoma
Intervention: Other: Serum and urinary CA9 level
12 Completed Clinical Study to Assess the Effects of SRT2104 and Prednisolone on Biomarkers in Blood in Healthy Volunteers
Conditions: Pulmonary Disease, Chronic Obstructive;   Healthy Volunteer
Interventions: Drug: Placebo;   Drug: 0.25g SRT2104;   Drug: Prednisolone;   Drug: 0.5g SRT2104;   Drug: 1g SRT2104;   Drug: 2g SRT2104
13 Completed
Has Results
Safety Study of Ivacaftor in Subjects With Cystic Fibrosis
Condition: Cystic Fibrosis
Interventions: Drug: Ivacaftor 25 mg/75 mg;   Drug: Ivacaftor 75 mg/150 mg;   Drug: Ivacaftor 150 mg or 250 mg;   Drug: Placebo
14 Active, not recruiting Drug Use Investigation for ARRANON G (Nelarabine) Injection 250mg
Condition: Cancer
Intervention: Drug: Nelarabine
15 Completed
Has Results
Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients
Conditions: Multidrug-resistant Tuberculosis;   Extensively Drug-resistant Tuberculosis
Intervention: Drug: Addition of different doses of clarithromycin.
16 Recruiting Trichomonas Vaginalis Repeat Infections Among HIV Negative Women
Condition: Vaginitis Trichomonal or Due to Trichomonas
Interventions: Drug: MTZ 250 mg BID;   Drug: MTZ 2 g
17 Completed Open-label, Dose-finding Study to Determine Antibody Response to G17DT Treatment in Patients With Gastric Cancer.
Condition: Gastric Cancer
Intervention: Biological: G17DT
18 Active, not recruiting Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy
Condition: Peanut Allergy
Interventions: Biological: Viaskin Peanut 50 mcg;   Biological: Viaskin Peanut 100 mcg;   Biological: Viaskin Peanut 250 mcg;   Biological: Viaskin Placebo
19 Completed
Has Results
Study of Phosphate Levels in Patients With Chronic Kidney Disease
Condition: Chronic Kidney Disease
Interventions: Drug: 1.25 g PA21 (250 mg iron);   Drug: 5.0 g PA21 (1,000 mg iron);   Drug: 7.5 g PA21 (1,500 mg iron);   Drug: 10.0 g PA21 (2,000 mg iron);   Drug: 12.5 g PA21 (2,500 mg iron);   Drug: Sevelamer hydrochloride
20 Completed
Has Results
A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients
Condition: Chronic Kidney Disease Requiring Chronic Dialysis
Interventions: Drug: PA21 (2.5 g tablet containing 500 mg iron);   Drug: Sevelamer carbonate;   Drug: PA21-1 (1.25 g tablet containing 250 mg iron)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years